Peptides; Massive commercial growth potential
Peptides are small or mini proteins that could function as neurotransmitters, hormones in the human body
They have been identified to be relatively safe, well tolerated and highly effective. Hence a rising interest in peptides in the Research and development units of Pharmaceuticals. Currently over 150 peptides therapeutics are undergoing clinical trials, showing massive opportunities in the future.
Suffice to say that, over 6000 different types peptides have been discovered, and these often have decisive roles in human physiology, including actions as growth factors, neurotransmitters, hormones, growth factors etc.
Peptides constitutes a perfect start off point for unusual therapeutics and their directness is definite in translating to tolerability, efficacy and perfect safety in human body, given their envious pharmacological design and distinctive dynamic compositions. Even so, the cost of production is lower compared to protein based substances.
There is no doubt that vast potentials awaits to be unraveled from peptides and its uses.
The wide range of use in;
- medicine is massive and
- Therapeutic peptide research is also witnessing a revival for commercial purposes.
An example is the pharmacological laboratory company that achieved global sales of more than US$2 billion of a peptide based product used for the treatment of prostate cancer and many more.
The peptide drug world market has been projected, at an estimated US$25 billion in 2018 from US$14 billion in 2011, with an underlying increase in unusual breakthrough peptide drugs of US$17 billion (66%) in 2018from US$9 billion in 2011 (60%).
In the treatment of obesity and diabetes, peptides drugs have been used largely and may be the reason why the Northern part of America typifiesthe highest share of the peptide drug market, the Asian market is depicted to have massively grown.
The peptide industry is highly massive in potential for commercial purposes in the coming years.